
==== Front
Breast Cancer Res Treat
Breast Cancer Res Treat
Breast Cancer Research and Treatment
0167-6806
1573-7217
Springer US New York

39002070
7427
10.1007/s10549-024-07427-2
Correction
Correction: Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Bhave Manali A. manali.ajay.bhave@emory.edu

1
Quintanilha Julia C. F. jquintanilha@foundationmedicine.com

2
Tukachinsky Hanna 2
Li Gerald 2
Scott Takara 2
Ross Jeffrey S. 23
Pasquina Lincoln 2
Huang Richard S. P. 2
McArthur Heather 4
Levy Mia A. 25
Graf Ryon P. 2
Kalinsky Kevin 1
1 grid.516089.3 0000 0004 9535 5639 Winship Cancer Institute, Emory University, 1365 Clifton Rd NE, Building B, Suite 4000, Atlanta, GA 30322 USA
2 https://ror.org/02ackr434 0000 0004 0599 7276 Foundation Medicine, Inc, 400 Summer Street, Boston, MA 02210 USA
3 https://ror.org/040kfrw16 grid.411023.5 0000 0000 9159 4457 Upstate Medical University, Syracuse, NY USA
4 grid.267313.2 0000 0000 9482 7121 University of Texas Southwestern, Dallas, TX USA
5 https://ror.org/01j7c0b24 grid.240684.c 0000 0001 0705 3621 Rush University Medical Center, Chicago, IL USA
13 7 2024
13 7 2024
2024
207 3 611614
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
issue-copyright-statement© Springer Science+Business Media, LLC, part of Springer Nature 2024
==== Body
pmcCorrection to: Breast Cancer Research and Treatment 10.1007/s10549-024-07376-w

The author would like to correct the typos in Figs. 1, 3 and 4 in the online published article.

In Fig. 1, Panel A: "3.3%" should be "33.3%" and in Panel B: "10.%" should be "10.4%".

In Fig. 3, Panel D: "PI3KCAmut" should be "PIK3CAmut".

In Fig. 4 Panel C: The labels "ESR1 WT" and "ESR1 mut" should be positioned slightly higher.

The corrected Figs. 1, 3 and 4 are shown below.Fig. 1 Prevalence of ESR1mut detected in tissue and liquid specimens of HR(+)HER2(−) mBC in the first three metastatic lines of therapy. ESR1mut detected in TBx (A) and LBx (B). AI aromatase inhibitors, chemo chemotherapy, CDK4/6i CDK 4/6 inhibitors, ET endocrine therapy, HR hormone receptor, LBx liquid biopsy, mBC metastatic breast cancer, mut mutations, SERD selective estrogen receptor degrader (fulvestrant), TBx tissue biopsy, TF ctDNA tumor fraction, Tx therapy

Fig. 3 Co-occurrence of ESR1mut and PI3K/AKT pathway alterations detected in tissue specimens of HR(+)HER2(−) mBC in the first three metastatic lines of therapy. loss copy loss, mut mutation, PI3K/AKT alterations include AKT1mut, PIK3CAmut, PTENmut, and PTENloss

Fig. 4 Clinical outcomes of HR(+)HER2(−) metastatic breast cancer patients receiving 1st-line AI + CDK4/6i by ESR1mut detected by TBx. Kaplan–Meier plots show rwTTD (A), rwPFS (B), and rwOS (C) for ESR1mut (n = 22) vs ESR1wt (n = 551). Swimmer plot shows rwTTD (each bar represents therapy duration on 1st line of therapy) and rwPFS (dots represent progression) for patients with ESR1mut ordered by specific ERS1mut (D). AI aromatase inhibitors, ESR1mut ESR1 mutations, ESR1WT ESR1 wild-type, HR hazard ratio, OS overall survival, PFS progression-free survival, rw real-world, TBx tissue biopsy, TTD time to treatment discontinuation

The original article has been corrected.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Manali A. Bhave and Julia C. F. Quintanilha have contributed equally to this work.
